Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06747923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06747923 · ClinicalTrials.gov record · last posted 2025-11-19

SB17170 Phase 2 Trial in IPF Patients

StatusRecruiting
PhasePhase 2
Started2025-01-27
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

Amendment record 6 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 6 times since 2024-12-20; most recent amendment 2025-11-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-06
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06747923
Lead Sponsor SPARK Biopharma
Conditions IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 30 participants
Start Date 2025-01-27
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-19